Caris Life Sciences, Inc. CAI
CAI among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
CAI and 9 peers, year by year
The 9 Health care companies closest to CAI in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences, Inc. | FY2025 | $812.0M | +97.0% | - | 5.6% | −8.4% | 8.2% | −11.8% | 0.66 |
| CORT Corcept Therapeutics Inc | FY2025 | $761.4M | +12.8% | - | 5.9% | 13.1% | 18.6% | 15.4% | - |
| BCRX Biocryst Pharmaceuticals Inc | FY2025 | $874.8M | +94.1% | - | 39.0% | 30.2% | 39.4% | n/m | n/m |
| IONS Ionis Pharmaceuticals Inc | FY2025 | $943.7M | +33.8% | - | −40.4% | −40.4% | −33.9% | −78.0% | 3.71 |
| BBIO BridgeBio Pharma, Inc. | FY2025 | $502.1M | +126% | - | −104.2% | −144.4% | −89.0% | n/m | n/m |
| WRBY Warby Parker Inc. | FY2025 | $871.9M | +13.0% | 54.0% | −0.6% | 0.2% | 5.0% | 0.4% | - |
| PBH Prestige Consumer Healthcare Inc. | FY2026 | $1.1B | −4.3% | 54.7% | 28.4% | 17.5% | 22.6% | 10.1% | 0.53 |
| TGTX TG Therapeutics, Inc. | FY2025 | $616.3M | +87.3% | - | 20.0% | 72.6% | −4.1% | 69.0% | 0.38 |
| ACAD Acadia Pharmaceuticals Inc | FY2025 | $1.1B | +11.9% | - | 9.8% | 36.5% | 9.8% | 31.9% | - |
| INSP Inspire Medical Systems, Inc. | FY2025 | $912.0M | +13.6% | 85.4% | 5.6% | 15.9% | 8.6% | 18.6% | - |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2023 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2023 to FY2025
Revenue as reported in the 10-K.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CAI Dec | $306.1M | $412.3M | $812.0M |
| CORT Dec | $482.4M | $675.0M | $761.4M |
| BCRX Dec | $331.4M | $450.7M | $874.8M |
| IONS Dec | $787.6M | $705.1M | $943.7M |
| BBIO Dec | $9.3M | $221.9M | $502.1M |
| WRBY Dec | $669.8M | $771.3M | $871.9M |
| PBH Mar | $1.1B | $1.1B | $1.1B |
| TGTX Dec | $233.7M | $329.0M | $616.3M |
| ACAD Dec | $726.4M | $957.8M | $1.1B |
| INSP Dec | $624.8M | $802.8M | $912.0M |
| Peer median | $624.8M | $705.1M | $874.8M |
Sales growth, FY2023 to FY2025
Revenue against the fiscal year before.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CAI Dec | - | +34.7% | +97.0% |
| CORT Dec | +20.0% | +39.9% | +12.8% |
| BCRX Dec | +22.4% | +36.0% | +94.1% |
| IONS Dec | +34.1% | −10.5% | +33.8% |
| BBIO Dec | −88.0% | n/m | +126% |
| WRBY Dec | +12.0% | +15.2% | +13.0% |
| PBH Mar | +3.8% | −0.2% | +1.1% |
| TGTX Dec | n/m | +40.8% | +87.3% |
| ACAD Dec | +40.4% | +31.8% | +11.9% |
| INSP Dec | +53.2% | +28.5% | +13.6% |
| Peer median | +21.2% | +30.2% | +13.6% |
Gross margin, FY2023 to FY2025
Gross profit / revenue.
Operating margin, FY2023 to FY2025
Operating income / revenue.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CAI Dec | −104.4% | −62.4% | 5.6% |
| CORT Dec | 22.2% | 20.3% | 5.9% |
| BCRX Dec | −31.3% | −0.6% | 39.0% |
| IONS Dec | −44.9% | −67.4% | −40.4% |
| BBIO Dec | n/m | −267.2% | −104.2% |
| WRBY Dec | −10.7% | −3.9% | −0.6% |
| PBH Mar | −2.0% | 30.4% | 29.6% |
| TGTX Dec | 8.8% | 12.7% | 20.0% |
| ACAD Dec | −10.1% | 24.1% | 9.8% |
| INSP Dec | −6.4% | 4.5% | 5.6% |
| Peer median | −8.3% | 4.5% | 5.9% |
Net margin, FY2023 to FY2025
Net income / revenue.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CAI Dec | −111.5% | −68.4% | −8.4% |
| CORT Dec | 22.0% | 20.9% | 13.1% |
| BCRX Dec | −68.4% | −19.7% | 30.2% |
| IONS Dec | −46.5% | −64.4% | −40.4% |
| BBIO Dec | n/m | −241.4% | −144.4% |
| WRBY Dec | −9.4% | −2.6% | 0.2% |
| PBH Mar | −7.3% | 18.6% | 18.9% |
| TGTX Dec | 5.4% | 7.1% | 72.6% |
| ACAD Dec | −8.4% | 23.6% | 36.5% |
| INSP Dec | −3.4% | 6.7% | 15.9% |
| Peer median | −7.9% | 6.7% | 15.9% |
Free cash flow, FY2023 to FY2025
Cash from operations minus capital spending.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CAI Dec | −$298.4M | −$253.6M | $66.9M |
| CORT Dec | $126.5M | $196.1M | $141.8M |
| BCRX Dec | −$97.3M | −$53.1M | $344.9M |
| IONS Dec | −$331.3M | −$546.2M | −$320.0M |
| BBIO Dec | −$529.0M | −$521.7M | −$447.0M |
| WRBY Dec | $7.3M | $34.7M | $43.7M |
| PBH Mar | $221.9M | $239.4M | $243.3M |
| TGTX Dec | −$31.4M | −$40.6M | −$25.0M |
| ACAD Dec | $16.7M | $157.2M | $105.1M |
| INSP Dec | $1.0M | $91.1M | $78.5M |
| Peer median | $1.0M | $34.7M | $78.5M |
FCF margin, FY2023 to FY2025
Free cash flow / revenue.
Return on equity, FY2023 to FY2025
Net income / shareholders' equity at the year end.
Debt / equity, FY2023 to FY2025
Total debt / shareholders' equity at the year end.
EPS (diluted), FY2023 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CAI Dec | −$13.24 | −$10.66 | −$3.22 |
| CORT Dec | $0.94 | $1.23 | $0.82 |
| BCRX Dec | −$1.18 | −$0.43 | $1.21 |
| IONS Dec | −$2.56 | −$3.04 | −$2.38 |
| BBIO Dec | −$3.95 | −$2.88 | −$3.78 |
| WRBY Dec | −$0.54 | −$0.17 | $0.01 |
| PBH Mar | −$1.65 | $4.17 | $4.29 |
| TGTX Dec | $0.09 | $0.15 | $2.77 |
| ACAD Dec | −$0.37 | $1.36 | $2.30 |
| INSP Dec | −$0.72 | $1.75 | $4.89 |
| Peer median | −$0.72 | $0.15 | $1.21 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out CAI and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: CAI's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CAI/export.csv") into a cell.